- Email: [email protected]
Antigens of Cysticercus cellulosae; used for antibody production, treatment of neurocysticercosis, diagnosis or vaccine production
Patent Report and a vaccinia virus, a recombinant vaccinia virus is constructed. The recombinant vaccinia virus may be incorporated into recombinant AIDS vaccines for humans. The recombinant vaccine may be used in AIDS prophylaxis or therapy. 006-91
Novel strain of influenza virus is useful in inactivated vaccine production Res. Inst. Influenza," Stand. Contr. Med. Biol. Prep USSR 1389 288; 30 October 1989 Novel strain B/Leningrad/104/84/20 of influenza virus is used in the preparation of inactivated vaccine. The strain is stored under the No. 1962 in GKV, and withstands up to 25 passages on developing chicken embryos. The new, highly reproducible strain is used in influenza vaccine preparation. 007-91
Recombinant DNA encoding hepatitis B virus polypeptide antigen is used in detection of infection and in vaccine production; production in prokaryotic or eukaryotic host; core antigen, surface antigen D N A sequence Biogen Eur. 374 869; 27 June 1990 A recombinant DNA molecule is characterized by a DNA sequence coding for a protein or fragment displaying hepatitis B virus (HBV) core antigen or surface antigen specificity, the sequence being operatively linked to an expression control sequence in the recombinant DNA molecule and being expressed to produce a protein displaying HBV antigen specificity in a suitable transformed host cell. Also claimed are a host cell transformed with the recombinant DNA molecule, and detection of HBV infections in serum using the DNA sequences. The sequences may also be used in vaccine production. More specifically, the protein displaying HBV antigen specificity also displays HBV antigenicity. The expression control sequence is preferably the lac system, the trp system, the major operator and promoter regions of phage lambda, or the control region of phage fd coat protein. Suitable hosts include Escherichia coli X1776, E. coli X2282, E. coli HB101, E. coli MRCI, strains of Pseudomonas, Bacillus subtilis etc., yeast, fungi, animal and plant cell culture. 008-91
Polypeptide derived from Plasmodium falciparum antigen GLURP; vector plasmid pRDI5 expression in Escherichia coli or Bacillus subtilis; recombinant vaccine construction and malaria therapy; monoclonal antibody and hyhridoma preparation Statens-Seruminst World 9002 811; 22 March 1990
Protein homologous to Trypanosoma cruzi heat shock protein; used in vaccine and diagnosis of e.g. Mycoplasma or Mycobacterium Codon World 9002 752; 22 March 1990 A vaccine is claimed comprising: (a) a protein capable of eliciting an antibody which recognizes at least one epitope of a native protein present in the organism, the native protein having at least 50% homology with a Trypanosoma cruzi heat shock protein (HSP); and (b) a physiologically acceptable carrier. The native protein is a HSP derived from Mycoplasma, Mycobacterium or Trypanosoma spp., especially from Mycoplasma hypopneumoniae and Mycoplasma 9allisepticum, but not from T. cruzi. The DNA sequences of both proteins are presented. Also claimed is a process for detecting an organism in a host, which involves contacting a sample derived from a host with an antigen which is recognized by an antibody elicited in response to a protein present in the organism, and determining antibody in the sample bound by the antigen, or an antibody or fragment recognizing at least one epitope of a native protein present in the organism. The proteins and/or fragments and/or derivatives having homology to HSPs of T. cruzi can be used in vaccines and for the diagnosis of Trypanosoma, Mycoplasma and Mycobacterium spp., especially with homologous DNA probes. 010-91
Transgenic plant expressing antigen of pathogenic organism; e.g. using Escherichia coli or Streptococcus mutans, used for oral immunization to inhibit colonization or invasion by pathogens Wash ing ton- Univ. World 9002 484; 22 March 1990 A transgenic plant (A) expressing a DNA sequence encoding an antigen (Ag) of a pathogenic organism is new. The Ag is either; (a) colonization Ag; (b) virulence Ag; (c) antigenic determinant of either Ag; or (d) fusion protein containing (a), (b) or (c). Also claimed is a composition for eliciting an immune response in a human or other animal which contains (A) or material from it. The pathogenic organism is: Antinomyces,
Aeromonas, Bacillus, Bacteroides, Bordetella, Brucella, Campylobacter, Capnocytopha,qa, Chlamydia, Clostridium, Corynebacterium, Eikenella, Escherichia, Erysipelothrix, Haemophilus, Klebsiella, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Nocardia, Pasteurella, Proteus, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Selenomonas, Treponema, Vibrio, Yersinia, adenovirus, coronavirus, herpesvirus, orthomyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rotavirus, Aspergillus, Blastomyces,
Candida, Giardia, Coccidiodes, Cryptococcus, Histoplasma, Phycomyces, Eimeria, Entamoeba or Trichomonas, especially Streptococcus mutans or Escherichia coli. 011 91
A Plasmodium falciparum antigen G L U R P of specified amino acid sequence and its derivatives are new. Also new is a polypeptide comprising a repeated subsequence of the ~, ~ and 7 repeats of G L U R P , where Pro does not occur at position three of the substantially repeated subsequence. The polypeptide preferably has a Glu composition of at least 20% and only one Met and no Cys residues. The polypeptide is preferably able to induce a proliferative response in a T-lymphocyte. The polypeptide may further comprise an amino acid sequence not derived from G L U R P , preferably ]~-glucosidase (EC 3.2.1.21), DNA encoding the polypeptide, an expression vector, preferably plasmid pRDI5, a recombinant organism (bacterium, fungus, yeast, insect cell, plant cell, mammal cell, etc.), transformed with the vector (preferably Escherichia coli or Bacillus subtilis, especially E. coli DSM 4815), a malaria recombinant vaccine, a method for preparing the polypeptides, a diagnostic agent, an immunoassay, a GLURP-specific monoclonal antibody (mAb) produced by a hybridoma, a method for preparing the mAb, and methods for polypeptide purification and monitoring are claimed. 009-91
68 Vaccine, Vol. 9, January 1991
Antigens of Cysticercus cellulosae; used for antibody production, treatment of neurocysticercosis, diagnosis or vaccine production Astra UK 2223 757; 18 April 1990 An antigen secreted by Cysticercus cellulosae is claimed which has an apparent mol.wt of 66 000 or 35 000, especially 90000 or 50 000, as estimated by SDS-PAGE. More specifically, the antigen has a partial amino acid sequence of Val-Glu-Tyr-ThrCys-Thr. Also claimed is an antibody to the antigen. The antigen is obtained from the in vitro culture medium of C. cellulosae. A vaccine against infestation of C. cellulosae is claimed comprising the antigen with a pharmaceutically acceptable carrier or diluent. The antigens and antibodies can be used in immunodiagnosis of neurocysticercosis in humans without any interference by other forms of systemic cysticercosis. Some of the antigens may confer protective immunity to the host, and may be used for developing vaccines to neutralize the infestations by C. cellulosae. 012-91
Novel strain of influenza virus is useful in inactivated vaccine production Res. Inst. Influenza," Stand. Contr. Med. Biol. Prep USSR 1389 288; 30 October 1989 Novel strain B/Leningrad/104/84/20 of influenza virus is used in the preparation of inactivated vaccine. The strain is stored under the No. 1962 in GKV, and withstands up to 25 passages on developing chicken embryos. The new, highly reproducible strain is used in influenza vaccine preparation. 007-91
Recombinant DNA encoding hepatitis B virus polypeptide antigen is used in detection of infection and in vaccine production; production in prokaryotic or eukaryotic host; core antigen, surface antigen D N A sequence Biogen Eur. 374 869; 27 June 1990 A recombinant DNA molecule is characterized by a DNA sequence coding for a protein or fragment displaying hepatitis B virus (HBV) core antigen or surface antigen specificity, the sequence being operatively linked to an expression control sequence in the recombinant DNA molecule and being expressed to produce a protein displaying HBV antigen specificity in a suitable transformed host cell. Also claimed are a host cell transformed with the recombinant DNA molecule, and detection of HBV infections in serum using the DNA sequences. The sequences may also be used in vaccine production. More specifically, the protein displaying HBV antigen specificity also displays HBV antigenicity. The expression control sequence is preferably the lac system, the trp system, the major operator and promoter regions of phage lambda, or the control region of phage fd coat protein. Suitable hosts include Escherichia coli X1776, E. coli X2282, E. coli HB101, E. coli MRCI, strains of Pseudomonas, Bacillus subtilis etc., yeast, fungi, animal and plant cell culture. 008-91
Polypeptide derived from Plasmodium falciparum antigen GLURP; vector plasmid pRDI5 expression in Escherichia coli or Bacillus subtilis; recombinant vaccine construction and malaria therapy; monoclonal antibody and hyhridoma preparation Statens-Seruminst World 9002 811; 22 March 1990
Protein homologous to Trypanosoma cruzi heat shock protein; used in vaccine and diagnosis of e.g. Mycoplasma or Mycobacterium Codon World 9002 752; 22 March 1990 A vaccine is claimed comprising: (a) a protein capable of eliciting an antibody which recognizes at least one epitope of a native protein present in the organism, the native protein having at least 50% homology with a Trypanosoma cruzi heat shock protein (HSP); and (b) a physiologically acceptable carrier. The native protein is a HSP derived from Mycoplasma, Mycobacterium or Trypanosoma spp., especially from Mycoplasma hypopneumoniae and Mycoplasma 9allisepticum, but not from T. cruzi. The DNA sequences of both proteins are presented. Also claimed is a process for detecting an organism in a host, which involves contacting a sample derived from a host with an antigen which is recognized by an antibody elicited in response to a protein present in the organism, and determining antibody in the sample bound by the antigen, or an antibody or fragment recognizing at least one epitope of a native protein present in the organism. The proteins and/or fragments and/or derivatives having homology to HSPs of T. cruzi can be used in vaccines and for the diagnosis of Trypanosoma, Mycoplasma and Mycobacterium spp., especially with homologous DNA probes. 010-91
Transgenic plant expressing antigen of pathogenic organism; e.g. using Escherichia coli or Streptococcus mutans, used for oral immunization to inhibit colonization or invasion by pathogens Wash ing ton- Univ. World 9002 484; 22 March 1990 A transgenic plant (A) expressing a DNA sequence encoding an antigen (Ag) of a pathogenic organism is new. The Ag is either; (a) colonization Ag; (b) virulence Ag; (c) antigenic determinant of either Ag; or (d) fusion protein containing (a), (b) or (c). Also claimed is a composition for eliciting an immune response in a human or other animal which contains (A) or material from it. The pathogenic organism is: Antinomyces,
Aeromonas, Bacillus, Bacteroides, Bordetella, Brucella, Campylobacter, Capnocytopha,qa, Chlamydia, Clostridium, Corynebacterium, Eikenella, Escherichia, Erysipelothrix, Haemophilus, Klebsiella, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Nocardia, Pasteurella, Proteus, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Selenomonas, Treponema, Vibrio, Yersinia, adenovirus, coronavirus, herpesvirus, orthomyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rotavirus, Aspergillus, Blastomyces,
Candida, Giardia, Coccidiodes, Cryptococcus, Histoplasma, Phycomyces, Eimeria, Entamoeba or Trichomonas, especially Streptococcus mutans or Escherichia coli. 011 91
A Plasmodium falciparum antigen G L U R P of specified amino acid sequence and its derivatives are new. Also new is a polypeptide comprising a repeated subsequence of the ~, ~ and 7 repeats of G L U R P , where Pro does not occur at position three of the substantially repeated subsequence. The polypeptide preferably has a Glu composition of at least 20% and only one Met and no Cys residues. The polypeptide is preferably able to induce a proliferative response in a T-lymphocyte. The polypeptide may further comprise an amino acid sequence not derived from G L U R P , preferably ]~-glucosidase (EC 3.2.1.21), DNA encoding the polypeptide, an expression vector, preferably plasmid pRDI5, a recombinant organism (bacterium, fungus, yeast, insect cell, plant cell, mammal cell, etc.), transformed with the vector (preferably Escherichia coli or Bacillus subtilis, especially E. coli DSM 4815), a malaria recombinant vaccine, a method for preparing the polypeptides, a diagnostic agent, an immunoassay, a GLURP-specific monoclonal antibody (mAb) produced by a hybridoma, a method for preparing the mAb, and methods for polypeptide purification and monitoring are claimed. 009-91
68 Vaccine, Vol. 9, January 1991
Antigens of Cysticercus cellulosae; used for antibody production, treatment of neurocysticercosis, diagnosis or vaccine production Astra UK 2223 757; 18 April 1990 An antigen secreted by Cysticercus cellulosae is claimed which has an apparent mol.wt of 66 000 or 35 000, especially 90000 or 50 000, as estimated by SDS-PAGE. More specifically, the antigen has a partial amino acid sequence of Val-Glu-Tyr-ThrCys-Thr. Also claimed is an antibody to the antigen. The antigen is obtained from the in vitro culture medium of C. cellulosae. A vaccine against infestation of C. cellulosae is claimed comprising the antigen with a pharmaceutically acceptable carrier or diluent. The antigens and antibodies can be used in immunodiagnosis of neurocysticercosis in humans without any interference by other forms of systemic cysticercosis. Some of the antigens may confer protective immunity to the host, and may be used for developing vaccines to neutralize the infestations by C. cellulosae. 012-91